Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2011

View Archived Issues

PSMA-ADC appears safe in first-in-human study in taxane-refractory metastatic CRPC

Interim phase I data support safety of tremelimumab plus bicalutamide in recurrent prostate cancer

Intraprostatic administration of PROSTVAC VF cancer vaccine is feasible and safe

Zymes receives Michael J. Fox Foundation grant to assess WS-CoQ10 for Parkinson's disease

Tariquidar is safe in combination with docetaxel in patients with cancer

Shire reviews progress of fourth quarter 2010

Multistage tuberculosis vaccine H-56 combats late-stage infection in vivo

Vical and U.S. government extend collaboration to develop vaccines against emerging diseases

Eisai's warfarin potassium tablets approved in Japan for pediatric use

Novel tyrosine-protein kinase SYK inhibitors described by IRM

Laboratorios Salvat presents novel APAF-1 inhibitors

Dainippon Sumitomo Pharma reports on third quarter fiscal 2010

Roche presents novel P2X7 receptor modulators

Sun Pharma and Caraco enter merger agreement

Proacta and Yakult Honsha enter PR-509 development agreement

Nesina approved in Japan for additional indications in type 2 diabetes

New HSL inhibitors claimed

Stamford Hospital participates in FDA's Expanded Access program for Generex Oral-lyn

Elan and PPD form global drug development collaboration

Phase III Heplisav trials cleared by safety monitoring board to continue

Argon Pharma discovers new prostaglandin G/H synthase 2 inhibitors

Delcath Systems receives FDA refusal to file letter for chemosaturation system

Tranzyme Pharma and Norgine start phase III trial of ulimorelin for postoperative ileus

Japanese approval granted for Sosei's NorLevo emergency contraceptive pill

FDA grants fast track status to Sunesis' Vosaroxin in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...